Signal from the log
N-Power Medicine
32 M$ · Series B · United States
N-Power Medicine anime un réseau de centres d'oncologie de ville aux États-Unis et y déploie ProECA, une technologie de bras de contrôle externes prospectifs qui remplace le groupe placebo d'un essai par des patients réels suivis en parallèle. Le tour vise l'extension au cancer colorectal et au cancer de la prostate.
Verified
Announced on , logged by the watch of 1 September 2026.
- Operation
- Funding round
- Announced amount
- 32 M$
- Stage
- Series B
- Country
- United States
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Labcorp Venture Fund , with Merck Global Health Innovation Fund , Innovatus Capital Partners
Provenance
Source businesswire
Logged on 1 September 2026
Description Written in French during the watch run. Based on the headline as relayed by the source, without reading the issuer's press release.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.